Phase I trial of SU14813 in patients with advanced solid malignancies.
Related Research units
Abstract
this phase I, open-label, dose-escalation study investigated SU14813, an oral multitargeted tyrosine kinase inhibitor, in adults with solid tumors.
Bibliographical data
| Original language | German |
|---|---|
| Article number | 1 |
| ISSN | 0923-7534 |
| Publication status | Published - 2011 |
| pubmed | 20605934 |
|---|
